Stock A225220 GENOLUTION INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genolution Inc.

Equities

A225220

KR7225220003

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-16 EDT 		5-day change 1st Jan Change
3,900 KRW -1.27% Intraday chart for Genolution Inc. +0.13% +1.69%
01-09 Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023. CI
01-09 Tranche Update on Genolution Inc.'s Equity Buyback Plan announced on July 10, 2023. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022
Capitalization 1 22,815 130,831 151,161 87,181
Enterprise Value (EV) 1 22,697 88,136 107,597 57,686
P/E ratio -19.5 x 0.82 x 2.17 x 2.9 x
Yield - - - -
Capitalization / Revenue 5.78 x 1.53 x 2.08 x 2.29 x
EV / Revenue 5.75 x 1.03 x 1.48 x 1.51 x
EV / EBITDA 50.7 x 1.62 x 2.54 x 3.59 x
EV / FCF - 3,663,561 x 5,843,762 x -3,743,387 x
FCF Yield - 0% 0% -0%
Price to Book 1.92 x 2.13 x 1.72 x 0.85 x
Nbr of stocks (in thousands) 12,713 19,326 19,326 19,373
Reference price 2 1,795 6,770 7,822 4,500
Announcement Date 12/31/20 3/1/21 12/31/22 3/1/23
1KRW in Million2KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022
Net sales 1 3,951 85,303 72,834 38,085
EBITDA 1 447.9 54,534 42,326 16,065
EBIT 1 148 54,041 41,281 14,737
Operating Margin 3.75% 63.35% 56.68% 38.69%
Earnings before Tax (EBT) 1 -287 43,281 43,533 17,239
Net income 1 -287 32,046 34,394 14,602
Net margin -7.26% 37.57% 47.22% 38.34%
EPS 2 -92.00 8,235 3,603 1,553
Free Cash Flow - 24,057 18,412 -15,410
FCF margin - 28.2% 25.28% -40.46%
FCF Conversion (EBITDA) - 44.11% 43.5% -
FCF Conversion (Net income) - 75.07% 53.53% -
Dividend per Share - - - -
Announcement Date 12/31/20 3/1/21 12/31/22 3/1/23
1KRW in Million2KRW
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022
Net Debt 1 - - - -
Net Cash position 1 118 42,696 43,564 29,494
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - 24,057 18,412 -15,410
ROE (net income / shareholders' equity) - 97.1% 47.9% 16.5%
ROA (Net income/ Total Assets) - 69.5% 28.9% 8.8%
Assets 1 - 46,112 119,119 165,985
Book Value Per Share 2 936.0 3,171 4,541 5,298
Cash Flow per Share 2 1,282 2,275 1,874 408.0
Capex 1 3,145 8,683 5,105 22,506
Capex / Sales 79.6% 10.18% 7.01% 59.09%
Announcement Date 12/31/20 3/1/21 12/31/22 3/1/23
1KRW in Million2KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
GENOLUTION INC. Stock Genolution Inc.
+1.69% 55.31M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-31.90% 9.3B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-6.25% 3.1B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+25.95% 2.87B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-13.96% 2.17B
VERACYTE, INC. Stock Veracyte, Inc.
-16.83% 1.75B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+72.82% 1.5B
CAREDX, INC Stock CareDx, Inc
+29.17% 807M
SEEGENE, INC. Stock Seegene, Inc.
-2.62% 759M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-26.33% 532M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. A225220 Stock
  4. Financials Genolution Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW